Clinical Trial Update: Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Trans Sodium Crocetinate in newly diagnosed glioblastoma biopsy-only subjects was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Trans Sodium Crocetinate (trans-sodium crocetinate)

Snippet

Sponsor: Diffusion Pharmaceuticals Inc | Conditions: Glioblastoma | Phase 3 | Status: TERMINATED | Results posted: 2021-07-22